Innovent Biologics (HKG:1801) said the new drug application for its anti-cancer drug ipilimumab injection "CTLA-4" monoclonal antibody was accepted by the Center for Drug Evaluation of the National Medical Products Administration of China, according to a Monday filing with the Hong Kong bourse.
The medicine also received a Priority Review designation in combination with sintilimab as neoadjuvant treatment for resectable microsatellite instability-high or mismatch repair deficient ("MSI-H/dMMR") colon cancer. This is China's first NDA for a domestic CTLA-4 inhibitor, the filing added.
The company's share prices were down over 3% in recent trading.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。